Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct 12:10:163-171.
doi: 10.4137/CMC.S38444. eCollection 2016.

A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure

Pupalan Iyngkaran  1 , Samia R Toukhsati  2 , Merlin C Thomas  3 , Michael V Jelinek  4 , David L Hare  5 , John D Horowitz  6
Affiliations
Review

A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure

Pupalan Iyngkaran et al. Clin Med Insights Cardiol. .

Abstract

Background: Beta-blockers (BBs) are the mainstay prognostic medication for all stages of chronic heart failure (CHF). There are many classes of BBs, each of which has varying levels of evidence to support its efficacy in CHF. However, most CHF patients have one or more comorbid conditions such as diabetes, renal impairment, and/or atrial fibrillation. Patient enrollment to randomized controlled trials (RCTs) often excludes those with certain comorbidities, particularly if the symptoms are severe. Consequently, the extent to which evidence drawn from RCTs is generalizable to CHF patients has not been well described. Clinical guidelines also underrepresent this point by providing generic advice for all patients. The aim of this review is to examine the evidence to support the use of BBs in CHF patients with common comorbid conditions.

Methods: We searched MEDLINE, PubMed, and the reference lists of reviews for RCTs, post hoc analyses, systematic reviews, and meta-analyses that report on use of BBs in CHF along with patient demographics and comorbidities.

Results: In total, 38 studies from 28 RCTs were identified, which provided data on six BBs against placebo or head to head with another BB agent in ischemic and nonischemic cardiomyopathies. Several studies explored BBs in older patients. Female patients and non-Caucasian race were underrepresented in trials. End points were cardiovascular hospitalization and mortality. Comorbid diabetes, renal impairment, or atrial fibrillation was detailed; however, no reference to disease spectrum or management goals as a focus could be seen in any of the studies. In this sense, enrollment may have limited more severe grades of these comorbidities.

Conclusions: RCTs provide authoritative information for a spectrum of CHF presentations that support guidelines. RCTs may provide inadequate information for more heterogeneous CHF patient cohorts. Greater Phase IV research may be needed to fill this gap and inform guidelines for a more global patient population.

Keywords: beta-blockers; chronic heart failure; comorbidity; external validity; review.

PubMed Disclaimer

Conflict of interest statement

Authors disclose no potential conflicts of interest. Disclosure All co-authors have won independent and governmental research funding. Several members provide counsel to pharmaceuticals. None pose a conflict of interest for this review.

Figures

Figure 1
Figure 1
Search strategy. Abbreviations: ββ, beta-blocker; RCT, randomized controlled trial.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Niederseer D, Thaler CW, Niederseer M, Niebauer J. Mismatch between heart failure in clinical trials and the real world. Int J Cardiol. 2013;168:1859–65. - PubMed
    1. Iyngkaran P, Majoni W, Cass A, et al. Northern territory perspectives on heart failure with comorbidities – understanding trial validity and exploring collaborative opportunities to broaden the evidence base. Heart Lung Circ. 2015;24(6):536–43. - PubMed
    1. Iyngkaran P, Beneby GS. Toward phase 4 trials in heart failure: a social and corporate responsibility of the medical profession. World J Methodol. 2015;5(4):179–84. - PMC - PubMed
    1. Iyngkaran P, Liew D, McDonald P, et al. Phase 4 research in heart failure – where are we and what should be done? Curr Cardiol Rev. 2016 Jun 6; Epub ahead of print. - PMC - PubMed
    1. Iyngkaran P, Thomas M. Bedside-to-bench translational research for chronic heart failure: creating an agenda for clients who do not meet trial enrollment criteria. Clin Med Insights Cardiol. 2015;9(suppl 1):121–32. - PMC - PubMed

LinkOut - more resources